CClinicalTrials.gg
CompletedNCT03720769Updated Apr 29, 2021

Testing e-Mental Health in Lebanon

An interventional study of Step-by-Step and Enhanced care as usual in Depression, sponsored by VU University of Amsterdam. Completed at 1 site in Lebanon. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-29.

Sponsored by VU University of Amsterdam · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
1,248
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study objective is to test a guided e-mental health intervention called Step-by-Step for people living in Lebanon. Step-by-Step is a self-help programme delivered through an app or website and aims to treat symptoms of depression and other symptoms of psychological distress. First, a small study will be conducted to test the research procedure. Second, a large study will be conducted to test the effectiveness of Step-by-Step.

People residing in Lebanon (i.e. Lebanese, Palestinians and Syrian displaced people), above the age of 18 with symptoms of depression will be recruited through social media, posters, radio and television adverts, etc. Minors (under the age of 18) and people who have plans to end their life will be excluded from the study.

To test whether the use of Step-by-Step improves symptoms of depression, two groups will be compared. Participants in the intervention group will receive Step-by-Step, while those in the control group will receive basic information about depression and a list of health centres where they can get face-to-face help that is based on evidence. In addition, participants in the intervention group will receive weekly phone or chat support (up to 15 minutes) provided through lay helpers who were trained and work under the supervision of a trained clinical psychologist. The study hypothesises that participants who receive Step-by-Step will have a higher symptom improvement than participants who receive basic information.

In order to assess symptoms of depression and other symptoms of psychological distress, participants in this study will complete several questionnaires three times: At the beginning of the study, after 8 weeks, and then three months later (i.e. 5 months after the beginning of the study).

02

Conditions studied

  • Depression

Browse trials for

03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's enrollment of 1,248 is above the median of 84 across 6,720 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

VU University of Amsterdam is the lead sponsor of 47 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18 or above
  • PHQ-9 sum score above 9
  • WHODAS 2.0 sum score above 16

Exclusion criteria

Exclusion Criteria:

  • Serious thoughts or plans to end one's life
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,248 participants (actual)

Study arms

  • Experimental
    Step-by-Step

    Behavioral: Step-by-Step

  • Active comparator
    Enhanced care as usual

    Behavioral: Enhanced care as usual

Interventions

  • BehavioralStep-by-Step

    Guided self-help programme delivered through an app/website for the treatment of depression

  • BehavioralEnhanced care as usual

    Psychoeducation and information about where to get help (i.e., mhGAP trained primary health care centres)

06

What researchers measure

Primary outcomes

  1. Patient Health Questionnaire (PHQ-9)

    Self-administered instrument for depression screening (intention-to-treat analysis)

    Time frame: 8 weeks

  2. WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)

    Generic assessment instrument for health and disability (intention-to-treat analysis)

    Time frame: 8 weeks

Secondary outcomes

  1. WHO-5 Well-Being Index

    Time frame: 8 weeks

  2. Generalized Anxiety Disorder - 7 Questionnaire (GAD-7)

    Time frame: 8 weeks

  3. PTSD Checklist for DSM-5 (PCL-6)

    Time frame: 8 weeks

  4. Self-defined psychosocial problems (PSYCHLOPS)

    Time frame: 8 weeks

  5. (Adapted) Client Service Receipt Inventory (CSRI)

    Time frame: 8 weeks

Other outcomes

  1. Client Satisfaction Questionnaire (CSQ-3)

    Time frame: only at post-assessment (8 weeks after baseline)

07

Study locations

1 site
  • Ministry of Public Health
    Beirut, Lebanon
08

References and documents

Publications

  • Cuijpers P, Heim E, Abi Ramia J, Burchert S, Carswell K, Cornelisz I, Knaevelsrud C, Noun P, van Klaveren C, Van't Hof E, Zoghbi E, van Ommeren M, El Chammay R. Effects of a WHO-guided digital health intervention for depression in Syrian refugees in Lebanon: A randomized controlled trial. PLoS Med. 2022 Jun 23;19(6):e1004025. doi: 10.1371/journal.pmed.1004025. eCollection 2022 Jun. Erratum In: PLoS Med. 2023 Apr 14;20(4):e1004231. doi: 10.1371/journal.pmed.1004231. PubMed 35737665 ↗
  • Cuijpers P, Heim E, Ramia JA, Burchert S, Carswell K, Cornelisz I, Knaevelsrud C, Noun P, van Klaveren C, Van't Hof E, Zoghbi E, van Ommeren M, El Chammay R. Guided digital health intervention for depression in Lebanon: randomised trial. Evid Based Ment Health. 2022 Dec;25(e1):e34-e40. doi: 10.1136/ebmental-2021-300416. Epub 2022 May 16. PubMed 35577536 ↗
  • van 't Hof E, Heim E, Abi Ramia J, Burchert S, Cornelisz I, Cuijpers P, El Chammay R, Harper Shehadeh M, Noun P, Smit F, van Klaveren C, van Ommeren M, Zoghbi E, Carswell K. Evaluating the Effectiveness of an E-Mental Health Intervention for People Living in Lebanon: Protocol for Two Randomized Controlled Trials. JMIR Res Protoc. 2021 Jan 28;10(1):e21585. doi: 10.2196/21585. PubMed 33507158 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03720769
Lead sponsor
VU University of Amsterdam
Collaborators
World Health Organization, Ministry of Public Health, Lebanon, Freie Universität Berlin
Responsible party
Pim Cuijpers (Professor, VU University of Amsterdam) — Principal investigator
First posted
Oct 25, 2018
Start date
Dec 9, 2019
Primary completion
Sep 16, 2020
Completion
Dec 20, 2020
Last update
Apr 29, 2021

Study contacts

Pim Cuijpers, Professor
principal investigator · VU Amsterdam

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion